Predict Antidepressant Responsiveness Using Pharmacogenomics
Information source: Samsung Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Depression; Depressive Symptoms
Intervention: SSRI treated group (Drug); non-SSRI treated group (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Samsung Medical Center Official(s) and/or principal investigator(s): Doh Kwan Kim, M.D., Ph.D., Principal Investigator, Affiliation: Samsung Medical Center
Overall contact: JungShil Back, B/Sc., Phone: 82-2-3410-0946, Email: jungshil.back@sbri.co.kr
Summary
The purpose of this study is to determine whether genetic information associated with
individual depressive symptoms.
Clinical Details
Official title: Predict Antidepressant Responsiveness Using Pharmacogenomics
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Presences of each individual symptom of depression at 1,2,4,6,12 weeks
Detailed description:
The primary hypothesis is that the variations of the candidate genes are associated with
individual symptoms in patients with depression.
The Second hypothesis is that patients with the associated genetic variation suffer longer
from the associated symptom than the patients without the associated genetic variation.
Eligibility
Minimum age: 19 Years.
Maximum age: 89 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Eligible patients were enrolled in the clinical trials program of hte Samsung Medical
Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a
semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The
affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the
Korean version of the structured clinical interview for the diagnostic and
statistical manual of mental disorders, Fourth edition.
- interview with one more patient's family member for objective diagnosis and final
diagnosis decision by agreements of two more psychiatric physicians
Exclusion Criteria:
- received psychotropic medication within 2 weeks of the study or fluoxetine within 4
weeks
- potential study participants for pregnancy, significant medical conditions, abnormal
laboratory baseline values, unstable psychiatric features(eg. suicidal), history of
alcohol of drug dependence, seizures, head trauma with loss of consciousness,
neurological illness, or concomitant Axis I psychiatric disorder.
Locations and Contacts
JungShil Back, B/Sc., Phone: 82-2-3410-0946, Email: jungshil.back@sbri.co.kr
Samsung Medical Center, Kangnam, Seoul, Korea, Republic of; Recruiting Doh Kwan Kim, MD.PhD, Phone: 82-2-3410-3582, Email: dohkwan.kim@samsung.com Woojae Myung, MD., Phone: 82-2-3410-6562, Email: smbhealer@gmail.com
Additional Information
Starting date: February 2003
Last updated: June 4, 2015
|